Patients whose atrial fibrillation lasts longer than seven days and who do not respond well to drug therapy are now eligible ...

The US Food and Drug Administration (FDA) has approved Boston Scientific’s expanded instructions for use (IFU) labelling of ...

Boston Scientific has claimed a new approval from the FDA for its Farapulse pulsed field ablation system, expanding its use ...

Undeniably, Barchart’s screener for unusual stock options volume is an important tool for deciphering market sentiment, ...

Boston Scientific receives US FDA approval for expanded labelling of Farapulse PFA System: Marlborough, Massachusetts Tuesday, July 8, 2025, 11:00 Hrs [IST] Boston Scientific Corp ...

Boston Scientific announces conference call discussing second quarter 2025 results. Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and ...

Boston Scientific has become a big deal-maker under chief executive Mike Mahoney. – Topher Cox. For over a decade before the Guidant bidding war, Boston Scientific had been an aggressive deal-maker.

Boston Scientific posted Q4 revenue of $4.56 billion, surpassing estimates. The company forecasts 2025 sales growth of up to 14.5% and EPS of $2.80-$2.87.